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Hemodialysis patients who live at high altitude use less exogenous erythropoietin but achieve higher hematocrit
levels than those living at a lower altitude. The authors hypothesized that the effect of altitude would be strongest in
hemodialysis patients with poor anemia treatment response. To explore this hypothesis, they studied anemia-
related outcomes in US hemodialysis patients who move to higher altitudes. Using Medicare and US Geological
Survey data, in 1992–2004 they identified instances in which a patient moved from a dialysis center at an altitude of
<2,000 feet (600 m) to one at a higher elevation. Of these moves, 5,274 were 3,000 feet (900 m; the altitude
group) and 25,345 were 250–500 feet (75–150 m; the control group). Among patients with poor treatment response
at baseline, large increases in hematocrit and decreases in erythropoietin dosing were observed in the altitude
relative to the control group. At 6 months, hematocrit had increased more in the altitude group (5.1%, 95%
confidence interval (CI): 4.1, 6.2 vs. 3.7%, 95% CI: 3.5, 3.9), and erythropoietin dosing decreased more (4,600
units/week, 95% CI: 500, 8,700 vs. 1,700 units/week, 95% CI: 1,000, 2,400). No effect of altitude was observed in
patients with better treatment response at baseline. These results support the hypothesis that altitude-induced
hypoxia reduces erythropoietin requirements in hemodialysis patients with treatment-refractory anemia.
altitude; anemia; erythropoietin; kidney failure, chronic; risk factors
Abbreviations: ESRD, end-stage renal disease; HIF, hypoxia-inducible transcription factor; USGS, United States Geological
Survey; USRDS, United States Renal Data System.
Patients with chronic kidney disease, including those re-
quiring chronic hemodialysis, produce insufficient amounts
of endogenous erythropoietin to maintain normal hematocrit
levels. Replacement of lost erythropoietin production by
administering recombinant human erythropoietin increases
hematocrit levels and reduces the need for red blood cell
transfusions in chronic kidney disease patients with anemia
(1–3). Some patients, however, exhibit persistent or inter-
mittent hyporesponsiveness to erythropoietin therapy and
fail to achieve target hemoglobin levels despite receiving
large erythropoietin doses (4, 5). Recent studies of hemodi-
alysis patients have found that hyporesponsiveness to
erythropoietin therapy is associated with elevated mortality
risk (6–9). An improved understanding of factors that in-
fluence erythropoietin response could lead to more effective
anemia management strategies and improved clinical
outcomes.
In Figure 1, we propose a simple model of the feedback
system that maintains hemoglobin concentrations. System
equilibrium is disturbed when the oxygen-carrying capacity
of the blood drops enough to activate hypoxia-inducible
transcription factors (HIFs), the key regulators of oxygen
homeostasis (10–12). In a healthy kidney, activation of
HIFs leads to expression of endogenous erythropoietin
and subsequent stimulation of erythropoiesis, provided that
iron is available (13). HIFs also affect expression of the
proteins involved in iron metabolism, such as transferrin,
concerned with iron transport, and transferrin receptor,
concerned with iron uptake (primarily by developing
erythrocytes) (14, 15). HIFs also exert a suppressive effect
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on hepcidin, a hormone that regulates iron availability and
absorption (16, 17).
In end-stage renal disease (ESRD), the feedback system
depicted in Figure 1 is disrupted because ESRD patients are
unable to produce sufficient amounts of erythropoietin to
fully correct their anemia. Inflammation also contributes
to anemia by down-regulating transferrin and up-regulating
hepcidin (16, 18). This process makes iron less accessible to
invading microorganisms but limits the iron available for
erythropoiesis. Indeed, what has been termed the ‘‘anemia
of chronic disease’’ is now thought to be caused primarily
by inflammation (19).
Similar to anemia, increased altitude may induce tissue
hypoxia because a lowered atmospheric partial pressure of
oxygen results in decreased loading of oxygen onto hemo-
globin. Therefore, moving to a higher altitude should trig-
ger increased activation of hypoxia-inducible factors in
certain cells and thus may influence many HIF-regulated
pathways. In healthy people, exposure to altitude leads to
increased erythropoiesis and an expansion of red blood cell
mass. In ESRD patients, altitude-induced hypoxia has been
shown to produce a negligible-to-small increase in endog-
enous erythropoietin expression by the diseased kidney
(20–22) but could have normal effects on the other systems
contributing to erythropoiesis, such as those involved with
iron metabolism (23).
In a recent study, it was reported that hemodialysis pa-
tients living at high altitude use less erythropoietin but
achieve higher hematocrit levels than apparently compara-
ble patients living at lower altitudes (24). Given the theoret-
ical effects of hypoxia on iron availability, we hypothesized
that the effect of altitude may be particularly strong in
ESRD patients, whose response to erythropoietin is limited
by the iron sequestration caused by inflammation. To ex-
plore this hypothesis, we studied the natural experiment that
occurs when dialysis patients move from a low to a higher
altitude. Using 13 years of data on all patients in Medicare’s
ESRD program, we identified a cohort of patients who
moved up from a dialysis center located below 2,000 feet
(600 m; 1 foot ¼ 0.3 m) to another one located at a higher
altitude. We examined how increased altitude affected both
achieved hematocrit levels and erythropoietin use. To de-
termine whether the effect of altitude was more pronounced
in patients with possible iron sequestration, we compared
the effect of altitude change in patients with a lower re-
sponse to erythropoietin with those with a greater treatment
response during the time period before the move.
MATERIALS AND METHODS
Data
We obtained data from the United States Renal Data Sys-
tem (USRDS) and the United States Geological Survey
(USGS). The USRDS contains detailed data on all patients
in Medicare’s ESRD program, including information
collected at dialysis initiation (reported on the Medical
Evidence Form, CMS-2728), describing demographics, pri-
mary cause of ESRD, clinical data (e.g., weight), and certain
laboratory measurements (e.g., serum albumin and hemato-
crit levels). In addition, the USRDS contains all Medicare
Part A and B claims that include information on diagnoses
and procedures recorded for all hospitalizations and outpa-
tient visits. The USRDS also contains claims for total
monthly erythropoietin doses, reported with the final hemat-
ocrit level recorded during the month.
From USGS data, we obtained a list of 137,061 US cities
along with their state and county Federal Information Pro-
cessing Standards code and their elevation. We also ob-
tained a list of US zip codes with their primary city and
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Figure 1. Physiologic model of the feedback system that regulates hemoglobin levels. ESRD, end-stage renal disease.
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the average elevation of the county, as reported by the
USGS. We then matched the zip code data to the USGS city
elevation data using city name, county, and state Federal
Information Processing Standards code. Doing so enabled
us to assign to each zip code the elevation of its primary city.
For zip codes that could not be matched to a city in the
USGS data, we set the elevation equal to the average eleva-
tion in the county. Altitudes were assigned to each dialysis
unit based on their zip code as reported in the USRDS
facility file.
The investigators obtained Data Use Agreements from
the National Institute of Digestive and Diabetes and Kidney
Diseases. The Brigham and Women’s Hospital Institutional
Review Board approved this research.
Patient selection
From the USRDS standard analytic files, we selected all
patients who initiated hemodialysis between January 1,
1992, and June 1, 2004. Patients were eligible for the
study as long as they remained on hemodialysis. Patients
became ineligible if they switched to peritoneal dialysis or
received a kidney transplant (because hematocrit levels
were no longer consistently available for these patients).
Eligibility also ended if patients were lost to follow-up,
reached the administrative end of follow-up (December
31, 2004), or died.
Patients were followed up for 12 months after moving to
a higher elevation. During each month in which patients
were eligible, we used the USGS data to determine the
approximate altitude of the dialysis center at which the pa-
tient received dialysis. Patients entered the study sample if
they received dialysis for 2 consecutive months at a center
located below 2,000 feet and then began receiving dialysis
at a center located at an elevation 250 feet (75 m) or more
higher than the dialysis center at which they were previously
treated. Study subjects also had to spend fewer than 5 days
in the hospital during the month before the move because
erythropoietin dosing information is unavailable for patients
while they are in the hospital. From this population, we
defined 2 study groups: 1) patients who moved to an altitude
of more than 3,000 feet (900 m), and 2) a control group of
patients who moved up 250–500 (150 m) feet. The control
group was required to move to ensure that the group was not
enriched with patients with greater disease severity and who
were unable to move.
We converted the total erythropoietin dose administered
during each month of follow-up into units per week by
multiplying the total monthly dose by 7 and then dividing
by the number of outpatient days in the month (total days
minus time spent in the hospital during the month). We
created 4 strata based on the hematocrit and erythropoietin
dosing during the 2-month baseline period before the move.
We first stratified the sample on the basis of the lower quin-
tile of hematocrit (<32% and 32%). We then created 2
additional strata within each of the hematocrit strata based
on the median erythropoietin dose within the strata: 13,700
units/week among patient with a hematocrit of less than
32% and 10,800 units/week among patients with a hemato-
crit of 32% or greater.
Statistical analysis
To characterize the patient groups, we computed sum-
mary statistics for a wide range of variables within strata
of hematocrit, erythropoietin dose, and altitude change. For
each group of patients, we assessed baseline hematocrit and
erythropoietin dosing during the 2-month baseline period.
To evaluate the effect of altitude change, we computed the
within-patient change in hematocrit and erythropoietin dose
for each month during the 12 months of follow-up. Patients
were censored at the time of death, transplant receipt, loss to
follow-up, or a subsequent move (up or down) of more than
1,000 feet (300 m).
To account for repeated observations within an individ-
ual, all statistical analyses evaluating the primary endpoints
(change in hematocrit level and change in erythropoietin
dose) were based on linear models estimated by using
generalized estimating equation methodology. These
approaches estimate parameters using an independence-
structured working variance-covariance matrix. This approach
computes asymptotically correct confidence intervals
when the data are dependent (e.g., clustered or repeated-
measures data) (25). We used the least-squares-means pro-
cedure within generalized estimating equations to estimate
population-averaged month-to-month changes in hematocrit
levels and erythropoietin doses. These regression models
were used to compute population-averaged (least-squares)
means and 95% confidence intervals for each statistic. This
approach uses the fitted regression model to estimate a mean
hematocrit and erythropoietin dose change standardized to
the distribution of covariates observed in the overall
population.
We conducted several secondary analyses to explore the
sensitivity of our results to confounding and informative
censoring. To adjust for possible confounding, we included
covariates in our regression models of change in both he-
matocrit and erythropoietin. The covariates included age,
sex, race, calendar year, weight, primary recorded cause
of ESRD (diabetes, hypertension, glomerulonephritis,
other), history of cancer, history of myocardial infarction,
erythropoietin use, and hematocrit in the baseline period. To
further explore the possibility of confounding, we examined
the effect of altitude change within strata of race. To inves-
tigate possible issues related to informative censoring, we
conducted analyses restricted to patients who moved and
remained at the new elevation for at least 6 months. To
explore the possibility of a dose-response relation, we con-
ducted an analysis in which the altitude group was redefined
to be patients who moved up to an altitude of 1,000–3,000
feet (rather than 3000 feet).
All statistical analyses were performed by using SAS
version 9.1 software (26).
RESULTS
Between 1992 and 2004, we identified 53,233 instances
in which hemodialysis patients who met the study entry
requirements moved from a dialysis center located below
2,000 feet to one located at least 250 feet higher. Of these
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instances, 5,274 involved moves of 3,000 feet or more (the
altitude group) and 25,345 involved moves of 250–500 feet
(the control group).
Table 1 presents the characteristics of the patients in these
2 groups stratified by hematocrit and average weekly eryth-
ropoietin dose before the move. Within each strata, patients
in the altitude group were similar to patients in the control
group with respect to age, body mass index (at start of di-
alysis), serum albumin (at start of dialysis), and history of
many medical comorbid conditions as reported on the med-
ical evidence form. However, race was strongly imbalanced
across groups. Black patients were underrepresented in the
altitude group, with 10%–20% being of black race com-
pared with 30%–40% in the control group. Patients in the
altitude group were very likely to be censored quickly,
mostly because of a move to a lower elevation during
follow-up. Of the 5,274 patients in the altitude group,
3,990 were censored 1 month after the move. After
12 months, only 462 patients remained uncensored. Of the
25,345 patients in the control group, only 1,133 were cen-
sored at 1 month. By 12 months after the move, 17,743
patients remained uncensored.
In Figures 2–5, we depict the change in hematocrit (upper
panel) and erythropoietin dose (lower panel) for each month
during follow-up for the altitude and control groups within
each stratum of baseline hematocrit and average weekly
erythropoietin use. Across all graphs, we found results con-
sistent with regression to the mean. For example, in patients
selected to have low hematocrit, we found increased hemat-
ocrit in both groups during follow-up. In patients with he-
matocrit of less than 32% who received more than the
median dose of erythropoietin during the baseline period
(patients who exhibited a poor response to erythropoietin
during the baseline period), we observed evidence of an
altitude effect (Figure 3).
In these patients, we detected large increases in hemato-
crit and decreases in erythropoietin dosing in the altitude
group relative to the control group. At 6 months, hematocrit
had increased in both groups, but more substantially in the
altitude group (3.7%, 95% confidence interval: 3.5, 3.9 in
the control group vs. 5.1%, 95% confidence interval: 4.1, 6.2
in the altitude group). Erythropoietin dosing decreased in
both groups, but by a greater amount in the altitude group
(1,700 units/week, 95% confidence interval: 1,000, 2,400 in
the control group vs. 4,600 units/week, 95% confidence in-
terval: 500, 8,700 in the altitude group). At 12 months, the
differences were more pronounced. Hematocrit had in-
creased similarly in the control group (3.7%, 95% confi-
dence interval: 3.5, 3.9) but by more in the altitude group
(6.3%, 95% confidence interval: 5.0, 7.6). Erythropoietin
Table 1. Baseline Characteristics of US Subjects in the Sample, by Elevation and Hematocrit Group, 1992–2004
Characteristic
Low Hematocrit and Low
EPO Dose
Low Hematocrit and High
EPO Dose
High Hematocrit and Low
EPO Dose


































No. % No. % No. % No. % No. % No. % No. % No. %
Male gender 1,387 48.5 303 55.8 1,508 51.1 244 52.3 5,147 54.1 1,311 56.6 5,114 51.0 1,085 55.4
Age, yearsa 67.0 20 67.0 20 62.1 0.2 61.7 0.5 68.0 19 68 17 66 20 67 19
Race
White 1,640 57.4 421 77.5 1,622 55.0 328 72.0 5,934 62.4 1,821 78.7 5,713 57.0 1,514 77.0
Black 1,114 49.7 61 11.2 1,239 42.0 90 19.7 3,216 33.8 250 10.8 3,953 39.4 511 11.9
History of myocardial
infarction
106 3.7 18 3.3 158 5.3 23 5.0 545 5.7 133 5.7 633 6.3 102 5.2
History of cancer 51 1.7 10 1.8 98 3.3 10 2.2 351 3.7 91 3.9 435 4.3 80 4.1
History of COPD 66 2.3 20 3.7 110 3.7 17 3.7 419 4.4 102 4.4 484 4.8 65 3.3
History of congestive
heart failure
359 12.6 58 10.7 540 18.3 90 19.7 1,983 20.8 438 18.9 2,387 23.8 380 19.4
History of dysrhythmia 78 2.7 12 2.2 100 3.4 21 4.6 397 4.2 85 3.7 430 4.3 84 4.3
History of PVD 136 4.7 30 5.5 223 7.5 30 6.6 958 10.1 226 9.7 1,000 10.0 213 10.9
History of diabetes 510 17.7 109 20.1 800 27.1 140 30.7 3,221 33.9 792 34.2 3,825 38.2 730 37.2
History of cerebrovascular
accident
107 3.6 28 5.2 134 4.5 19 4.2 629 6.6 134 5.8 656 6.5 96 5.0
History of ischemic
heart disease
249 8.7 41 7.6 391 13.3 53 11.6 1,733 18.2 399 17.2 1,994 19.9 334 17.0
Body mass index, kg/m2a 25.0 7.6 23.9 6.9 26.6 9.3 26.8 9.9 25.5 7.7 25.2 7.2 26.6 8.7 26.7 8.4
Serum albumin, g/dLa 3.3 0.8 3.3 0.9 3.2 0.8 3.1 0.9 3.3 0.9 3.3 0.9 3.3 0.9 3.3 0.9
Abbreviations: COPD, chronic obstructive pulmonary disease; EPO, erythropoietin; PVD, peripheral vascular disease.
a Values are expressed as median (interquartile range).
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dosing decreased 2,000 units/week (95% confidence inter-
val: 1,200, 2,900) in the control group and 8,100 units/week
(95% confidence interval: 3,400, 12,800) in the altitude
group. We observed relatively little effect of altitude in
the remaining patient subgroups (Figures 2, 4, and 5). There
was some evidence that erythropoietin dosing was slightly
reduced in patients with low hematocrit and low dose as
well as in the patients with high hematocrit and high dose
(Figures 2 and 5).
The sensitivity analysis in which we adjusted for baseline
covariates produced results that were quantitatively similar.
We also found similar results when the analysis was re-
stricted to white patients. There were insufficient numbers
of patients of other race groups to conduct analyses re-
stricted to other races. When we restricted our analysis to
patients who were uncensored at 6 months, we observed
similar point estimates but larger standard errors for earlier
months. Finally, in our analysis comparing patients who
moved up 1,000–3,000 feet with patients who moved up
only 250–500 feet, we observed a smaller effect of altitude
on change in erythropoietin dosing, suggestive of a graded
dose-response effect of altitude.
Figure 2. Change in hematocrit (top panel) and erythropoietin (EPO) use (bottom panel), by altitude exposure group, among US patients with
hematocrit <32% and average EPO use <13,700 units/week before the altitude change, 1992–2004. One foot ¼ 0.3 m.
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DISCUSSION
We studied the effect of an altitude increase on anemia
management and hemoglobin outcomes among mainte-
nance hemodialysis patients. We found that the effect of
increased altitude appears to be localized in patients with
low hematocrit who received larger erythropoietin doses
during the 2-month baseline period. Among these patients,
those who moved to a higher altitude and began receiving
dialysis at a center located 3,000 feet or more higher than
their previous center experienced a greater increase in he-
matocrit than did similar patients who moved up only 250–
500 feet. These same patients also experienced a decrease in
erythropoietin dosing relative to the control patients. The
changes in hematocrit and erythropoietin dosing were evi-
dent after a few months, but they became more pronounced
6–12 months after the altitude change. We found relatively
little evidence of an effect of altitude in the remaining pa-
tient subgroups, that is, those with higher hematocrit levels
or those with low hematocrit levels who were receiving low
doses of erythropoietin. These findings are consistent with
a previous cross-sectional analysis reporting decreased
erythropoietin use but higher achieved hematocrit levels in
Figure 3. Change in hematocrit (top panel) and erythropoietin (EPO) use (bottom panel), by altitude exposure group, among US patients with
hematocrit <32% and average EPO use 13,700 units/week before the altitude change, 1992–2004. One foot ¼ 0.3 m.
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hemodialysis patients residing at higher altitude (24). The
present study builds on the previous research in that it sug-
gests that the effect of altitude is manifest largely in patients
who do not respond well to erythropoietin.
Given the theoretical effects of altitude described previ-
ously, we speculated that ESRD patients moving to a high
altitude would have more iron available for erythropoiesis.
Among ESRD patients who exhibit poor response to eryth-
ropoietin as a result of sequestration of iron, we hypothe-
sized that an increase in altitude would result in increased
release of stored iron and a subsequent improvement in
erythropoietin response. In ESRD patients whose response
to erythropoietin is not limited by iron availability, we
hypothesized that increased altitude would have little effect
on erythropoietin responsiveness. These hypotheses are
consistent with our observation that an increase in altitude
appears to affect primarily patients with low hematocrit
levels prior to the move. These are patients who tend to have
greater comorbidity burden (27, 28) and higher levels of
inflammation (29–31), and who may not respond well to
erythropoietin therapy in part because of the sequestration
of iron.
Figure 4. Change in hematocrit (top panel) and erythropoietin (EPO) use (bottom panel), by altitude exposure group, among US patients with
hematocrit 32% and average EPO use <10,800 units/week before the altitude change, 1992–2004. One foot ¼ 0.3 m.
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We are aware of several limitations of our research.
First, we anticipated that the longitudinal study design
would result in a ‘‘natural experiment.’’ However, we
found that patients who move up 3,000 feet or more are
different in various observed ways from those who move
up 250–500 feet. Although our results were based on
within-person comparisons and were therefore less sub-
ject to confounding by static patient characteristics, it is
still possible that unmeasured characteristics may con-
found the analysis. For example, people who move up
3,000 feet or more may be healthier and more likely to
experience a large increase in hematocrit. In support of
our findings, we note that statistical adjustment for several
important observed factors that we would expect to be
associated with erythropoietin response did not qualita-
tively change our results. It is also possible that observed
differences between groups is a result of different treat-
ment practices in dialysis centers at higher altitude. How-
ever, this would not explain why the differences between
groups were observed only in those patients with low
Figure 5. Change in hematocrit (top panel) and erythropoietin (EPO) use (bottom panel), by altitude exposure group, among US patients with
hematocrit 32% and average EPO use 10,800 units/week before the altitude change, 1992–2004. One foot ¼ 0.3 m.
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hematocrit who were receiving high doses of erythropoi-
etin prior to the move.
Second, it is possible that the effects we observed are
not due to altitude-induced hypoxia but are instead a result
of environmental factors associated with higher altitude,
such as temperature, sunlight intensity, humidity, or
concentrations of ambient particulate matter. These pos-
sibilities would have to be explored in an analysis that
appropriately accounts for such factors. Third, other
physiologic changes are known to occur at altitude that
could affect our results, including changes in plasma and
red cell volume (32, 33). Patients with ESRD have limited
ability to regulate plasma volume, but increased red cell
volume at altitude could lead to increased hematocrit
without any change in erythropoiesis. Nevertheless, if
such a phenomenon were occurring, we would expect to
find it in all patients, not just those with low hematocrit
prior to the move.
Our research was also limited by the absence of iron-
related laboratory test results in the database and accurate
information about iron dosing. We have speculated that the
effect of altitude on anemia and erythropoietin requirements
may exist primarily in patients with a functional iron de-
ficiency caused by inflammation. With data that include
measures of ferritin and transferrin saturation, this hypoth-
esis could be more directly tested. Without such data, how-
ever, we cannot rule out other physiologic mechanisms for
the associations we observed.
Given the many potential physiologic effects of altitude in
patients with kidney disease (34), there has been an interest
in understanding how altitude may affect various clinical
outcomes in patients with ESRD (35). The design we pro-
pose here could be used along with a conventional cross-
sectional analysis to robustly explore the effect of altitude
and altitude change on clinical outcomes in hemodialysis
patients.
Hypoxia and inflammation are known to be opposing
forces affecting erythropoiesis. Inflammation impairs
erythropoiesis, whereas hypoxia promotes erythropoiesis.
Our results raise the possibility that altitude-induced
hypoxia may enhance erythropoietin response in patients
who do not respond well to erythropoietin as a result of
inflammation. Our findings and related research suggest
that erythropoietin hyporesponsiveness could be alleviated
through therapeutic interventions that either mimic hy-
poxia or selectively suppress components of inflammation.
Some effects of hypoxia can be induced by pharmacologic
stabilization of HIF-1a, the oxygen-sensing subunit of
the HIF-1 transcription factor (11). Similarly, a wide vari-
ety of compounds are known to exert antiinflammatory
effects that may improve erythropoiesis in poorly respon-
sive patients. For example, pharmacologic inhibition of
the receptor for interleukin-6, a proinflammatory cytokine
that induces hepcidin expression, has been reported to
increase hemoglobin levels in patients with rheumatoid
arthritis (36). Future research examining the use of eryth-
ropoietin in combination with hypoxia-mimicking or
inflammation-suppressing therapies may help to identify
more effective anemia management strategies for patients
with ESRD.
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